ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	EUCTR
Last refreshed on:	9 October 2012
Main ID:	EUCTR2005-005581-36-SE
Date of registration:	15/10/2008
Prospective Registration:	Yes
Primary sponsor:	Bayer Schering Pharma AG
Public title:
Scientific title:	Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancer -
Date of first enrolment:	26/11/2008
Target sample size:	72
Recruitment status:	Not Recruiting
URL:	https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005581-36
Study type:	Interventional clinical trial of medicinal product
Study design:	Controlled: no Randomised: yes Open: Single blind: Double blind: Parallel group: Cross over: Other: If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no
Phase:

Countries of recruitment
Austria	Finland	Germany	Italy	Spain	Sweden	United Kingdom

Contacts

Name:
Address:
Telephone:
Email:
Affiliation:

Name:
Address:
Telephone:
Email:
Affiliation:

Key inclusion & exclusion criteria

Inclusion criteria:
Patients must meet all of the following inclusion criteria:

1. Postmenopausal women defined as:
- aged >/= 50 years with amenorrhea for at least 12 months or
- aged stimulating
- hormone (FSH) level within postmenopausal range (> 40 mIU/ml) or
- having undergone bilateral oophorectomy

2. Histologically or cytologically confirmed breast cancer

3. Metastatic breast cancer (Stage IV according to UICC – Union internationale
Contre Cancer - criteria)

4. Progesterone receptor (PR)-positive tumors

5. Patients must be considered candidates for endocrine therapy (no other
therapies for breast cancer are required)

6. Disease progression after first-line endocrine therapy for advanced breast cancer
(i.e. with tumor remission or stabilization lasting at least 3 months under
endocrine therapy)

7. At least one measurable or non measurable tumor lesion (according to RECIST
criteria)

8. WHO Performance status 1 or lower

9. Adequate function of major organs and systems

Hematopoietic:
- Hemoglobin: >= 10 g/dL
- Absolute neutrophil count: >= 1,500/mm3
- Platelet count: >= 100,000/mm3

Hepatic:
- Total bilirubin: <=1.5 times the upper limit of normal
- AST/ALT: <=2.5 times the upper limit of normal

Renal:
- Creatinine: <=1.5 times the upper limit of normal

Gynecological:
- Endometrial thickness (in non-hysterctomised women)
= 10 mm double layer
An endometrial biopsy needs to be performed if endometrial thickness increases by more than 2 mm compared to baseline or if clinical symptoms of endometrial changes (e.g. vaginal bleeding) occur.

No other uncontrolled concurrent illness

10. Adequate recovery from previous surgery, radiation and chemotherapy

11. Written informed consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Patients who meet any of the following criteria will be excluded:

1. Presence of any of the following conditions:
- life-threatening metastatic visceral disease (extensive hepatic involvement)
- any metastases to the central nervous system (CNS)
- pulmonary lymphangitic metastases involving more than 50% of the lung

2. More than one prior endocrine treatment for advanced breast cancer

3. The following previous treatments should not be excluded:
• one first line previous chemotherapy for metastatic disease
• combination therapy of 2 endocrine agents (e.g. aromatase inhibitors and anti-estrogen)
• previous sequential endocrine treatment with aromatase inhibitors or anti estrogens (if there was no disease progression between the treatments).
The following previous treatments should be excluded:
• Combination of endocrine therapy with an investigational drug (e.g. anti-angiogenic treatment)

4. Patients with breast cancer HER-2 positive or unknown HER-2 status are not eligible

5. Malignancies or history of prior malignancy other than carcinoma in situ of the cervix or uterus, or basal and squamous cell carcinoma of the skin

6. Intake of CYP3A4 inhibitors less than 2 weeks before start of study treatment

7. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds (ms))

8. A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)

9. The use of concomitant medications that prolong the QT/QTc interval

10. Discontinuation of any non endocrine investigational drug therapy 4 weeks or at least 5 half lives before start of treatment (4 weeks for faslodex and 2 weeks for any other endocrine therapy)

11. Expectation that the patient will not be able to complete at least 3 months of therapy

12. Unwillingness or inability to comply with the protocol

Age minimum:
Age maximum:
Gender:
Female: yes
Male: no

Health Condition(s) or Problem(s) studied

Metastatic breast cancer
MedDRA version: 9.1 Level: LLT Classification code 10027475 Term: Metastatic breast cancer

Intervention(s)

Product Name: ZK 230211
Product Code: SH T00208FA
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: lonaprisan
CAS Number: n/a
Current Sponsor code: ZK 230211
Other descriptive name: ZK PRA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25 -

Product Name: ZK 230211
Product Code: SH T00208GA
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: lonaprisan
CAS Number: n/a
Current Sponsor code: ZK 230211
Other descriptive name: ZK PRA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-

Primary Outcome(s)

Main Objective: To evaluate efficacy (clinical benefit) of two doses of ZK PRA (25 mg and 100 mg) when administered once daily p.o.

Primary end point(s): Clinical Benefit (CB): proportion of patients with:

- Complete response (CR) or partial response (PR) at any time point

or

- Stable disease (SD) for 6 months from the start of study treatment

Secondary Objective: - To evaluate safety and tolerability
- To evaluate the pharmacokinetics of ZK PRA
- To evaluate the effect of ZK PRA on quality of life (QoL)
- To perform exploratory analysis of biomarkers

Secondary Outcome(s)

Secondary ID(s)

309821

2005-005581-36-AT

N/A

Source(s) of Monetary Support

Secondary Sponsor(s)

Ethics review

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.